The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Lineage plasticity in EFGR-mutant lung cancer
Ryan Gentzler, MD, University of Virginia, Charlottesville, VA, provides an overview of current research on lineage plasticity in lung cancer. Lineage plasticity, which involves cancer cells changing cell type, can be a mechanism of resistance to immunotherapies and targeted therapies in 5-10% of patients with EFGR-mutant lung cancer. Biopsies can detect lineage plasticity in cells, and whilst more research is required to overcome this, current options in small cell lung cancer (SCLC) include platinum- or etoposide-based chemotherapies. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC22).
